Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

NeuroPace (NPCE) Interest & Investment Income (2021 - 2025)

Historic Interest & Investment Income for NeuroPace (NPCE) over the last 5 years, with Q3 2025 value amounting to $667000.0.

  • NeuroPace's Interest & Investment Income fell 1153.85% to $667000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 million, marking a year-over-year decrease of 966.82%. This contributed to the annual value of $3.0 million for FY2024, which is 85.25% down from last year.
  • As of Q3 2025, NeuroPace's Interest & Investment Income stood at $667000.0, which was down 1153.85% from $718000.0 recorded in Q2 2025.
  • NeuroPace's Interest & Investment Income's 5-year high stood at $827000.0 during Q1 2024, with a 5-year trough of $26000.0 in Q1 2021.
  • For the 5-year period, NeuroPace's Interest & Investment Income averaged around $540947.4, with its median value being $718000.0 (2025).
  • As far as peak fluctuations go, NeuroPace's Interest & Investment Income soared by 44179.1% in 2023, and later plummeted by 1715.33% in 2024.
  • Quarter analysis of 5 years shows NeuroPace's Interest & Investment Income stood at $186000.0 in 2021, then skyrocketed by 330.11% to $800000.0 in 2022, then rose by 2.75% to $822000.0 in 2023, then decreased by 17.15% to $681000.0 in 2024, then decreased by 2.06% to $667000.0 in 2025.
  • Its last three reported values are $667000.0 in Q3 2025, $718000.0 for Q2 2025, and $793000.0 during Q1 2025.